Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights

March 24, 2026 - 18:04

Biomea Fusion has announced its full-year financial results for 2025, highlighting significant progress across its clinical pipeline. The company is moving forward with multiple mid-to-late-stage trials for its lead metabolic disease candidates.

A major focus remains on icovamenib for diabetes. The firm has initiated two new Phase II studies, COVALENT-211 and COVALENT-212, evaluating the drug in patients with type 2 diabetes. Primary endpoint data from these 26-week trials is anticipated in the fourth quarter of 2026. Additionally, the company has completed the 52-week follow-up period for its Phase II COVALENT-112 trial in type 1 diabetes, with results expected in the second quarter of 2026.

Beyond diabetes, Biomea is expanding into the obesity treatment arena. Enrollment has begun for a Phase I trial of GLP-131, also known as BMF-650. Initial 28-day weight reduction data from this study is projected for release in the second quarter of 2026.

Financially, the company reported that its current cash and equivalents are sufficient to fund its operating plans and capital expenditure requirements into the first quarter of 2027. This extended runway is expected to support the advancement of these key clinical programs through several upcoming data readouts. The company's strategy centers on developing covalent therapies designed to offer durable benefits for chronic metabolic conditions.